The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

Kimberly Webster, David Cella, Kathleen Yost, Kimberly Webster, David Cella, Kathleen Yost

Abstract

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. The measurement system, under development since 1987, began with the creation of a generic CORE questionnaire called the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-G (now in Version 4) is a 27-item compilation of general questions divided into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. It is appropriate for use with patients with any form of cancer, and extensions of it have been used and validated in other chronic illness condition (e.g., HIV/AIDS; multiple sclerosis; Parkinson's disease; rheumatoid arthritis), and in the general population. The FACIT Measurement System now includes over 400 questions, some of which have been translated into more than 45 languages. Assessment of any one patient is tailored so that the most-relevant questions are asked and administration time for any one assessment is usually less than 15 minutes. This is accomplished both by the use of specific subscales for relevant domains of HRQOL, or computerized adaptive testing (CAT) of selected symptoms and functional areas. FACIT questionnaires can be administered by self-report (paper or computer) or interview (face-to-face or telephone). Available scoring, normative data and information on meaningful change now allow one to interpret results in the context of a growing literature base.

References

    1. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston IL, Version 4. 1997.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Lloyd S, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor S, Thomas C, Harris J. The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570–579.
    1. Webster K, Odom L, Peterman A, Lent L, Cella D. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res. 1999;8:604.
    1. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol. 1997;15:974–986.
    1. Weitzner MA, Meyers CA, Gelke C, Byrne K, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75:1151–1161.
    1. Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8:181–195. doi: 10.1023/A:1008821826499.
    1. List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. The Performance Status Scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) scale: A study of utility and validity. Cancer. 1996;77:2294–2301. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>;2-T.
    1. Heffernan N, Cella D, Webster K, Odom L, Marone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. Measuring health-related quality of life in patients with hepatobiliary cancers: The Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep) questionnaire. J Clin Oncol. 2002;20:2229–2239. doi: 10.1200/JCO.2002.07.093.
    1. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy – Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220. doi: 10.1016/0169-5002(95)00450-F.
    1. Webster K, Chivington K, Shonk C, Eremenco S, Yount S, Hahn E, van Gool R, Tallman M, Cella D. Measuring quality of life (QOL) among patients with leukemia: The Functional Assessment of Cancer-Therapy-Leukemia (FACT-Leu) Qual Life Res. 2002;11:678.
    1. Basen-Enquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) J Clin Oncol. 2001;19:1809–1817.
    1. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring Quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Urology. 1997;50:920–928. doi: 10.1016/S0090-4295(97)00459-7.
    1. McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi AE, Hurd DD. Quality of life measurement in bone marrow transplantation: Development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) scale. Bone Marrow Transplant. 1997;19:357–368. doi: 10.1038/sj.bmt.1700672.
    1. Bacik J, Mazumdar M, Fairclough DL, Murphy B, Mariani T, Motzer R, Cella D. The Functional Assessment of Cancer Therapy-BRM (FACT-BRM): A New Tool for the Assessment of Quality of Life in Patients Treated with Biologic Response Modifiers. Qual Life Res.
    1. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt T, Cella D. Psychometric Evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741–748. doi: 10.1111/j.1525-1438.2003.13603.x.
    1. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) Cancer. 2003;98:822–831. doi: 10.1002/cncr.11578.
    1. Ribaudo J, Cella D, Hahn EA, Lloyd S, Tchekmedyian NS, VonRoenn J, Leslie W. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137–1146. doi: 10.1023/A:1016670403148.
    1. Yellen SB, Cella DF, Webster KA, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74. doi: 10.1016/S0885-3924(96)00274-6.
    1. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189–199. doi: 10.1023/A:1006263818115.
    1. Peterman AH, Fitchett G, Brady M, Hernandez L, Cella D. Measuring spiritual well-being in people with cancer: The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp) Ann Behav Med. 2002;24:49–58. doi: 10.1207/S15324796ABM2401_06.
    1. Peterman AH, Cella DF, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997;6:572–584. doi: 10.1023/A:1018416317546.
    1. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Mo F, Stewart J, Stefoski D. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. Neurology. 1996;47:129–139.
    1. Hahn EA, Cella D. Unbiased quality of life measurement across literacy levels and mode of administration. Qual Life Res. 1997;6:654.
    1. Hahn EA. The Talking Touchscreen: a new approach to outcomes assessment in low literacy. Psycho-Oncology.
    1. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371–383.
    1. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res. 1993;2:221–226.
    1. Cella D, Eton DT, Lai JS, Peterman A, Merkel DE. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales. J Pain Symptom Manage. 2002;24:547–561. doi: 10.1016/S0885-3924(02)00529-8.
    1. Cella D, Hahn E, Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res. 2002;11:207–221. doi: 10.1023/A:1015276414526.
    1. McCain NL, Zeller JM, Cella D, Urbanski PA, Novak RM. The influence of stress management training in HIV disease. Nursing Res. 1996;45:246–253.
    1. Eton D, Cella D, Yost K, Yount S, Peterman A, Sledge G. Minimally important differences on the Functional Assessment of Cancer Therapy-Breast (FACT-B) scale: Results from ECOG Study 1193. J Clin Epidemiol.
    1. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39:335–345. doi: 10.1016/S0959-8049(02)00628-7.
    1. Yost K, Eton D, Cella D, Ayanian JZ, Zaslavsky A, West DW. Minimal important differences on the Functional Assessment of Cancer Therapy-Colorectal. Qual Life Res. 2002;11:629.
    1. Ringash J, Bezjak A, O'Sullivan B, Redelmeier DA. Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients. Qual Life Res.
    1. Cella DF, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf M, Johnson D. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy – Lung (FACT-L): Results from the Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55:285–295. doi: 10.1016/S0895-4356(01)00477-2.

Source: PubMed

3
Tilaa